Trial Profile
A phase II trial pemetrexed carboplatin as first line chemotherapy for advanced non - small cell lung cancer (NSCLC) in elderly patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Oct 2010
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 22 Dec 2009 Actual patient number (62) added as reported by ClinicalTrials.gov.
- 22 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.